Hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma with portal vein thrombosis: a case–control study

Abdelmaksoud, Ahmed Hosni; Abdelaziz, Ashraf Omar; Nabeel, Mohamed Mahmoud; Hamza, Iman; Elbaz, Tamer; Shousha, Hend Ibrahim; Abdelhady, R.S.M.; Lithy, Rania

doi:10.1016/j.crad.2021.03.022

Cited by 6 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients must also be able to tolerate the often simultaneously administered SCT. HAI in patients with Child-Pugh A liver disease has shown to be feasible and safe and can potentially offer a less toxic treatment option than systemic monotherapy in patients with Child-Pugh B cirrhosis [ 20 , 21 ].…”

Section: Indication and Contraindicationmentioning

confidence: 99%

Hepatic Artery Infusion Chemotherapy for Primary and Secondary Malignancies of the Liver: State of the Art and Current High-Level Evidence

Kuemmerli,

Hess,

Dutkowski

et al. 2024

Pharmacology

View full text Add to dashboard Cite

Background Hepatic artery infusion chemotherapy (HAI) has been proposed as a valuable adjunct for multimodal therapy of primary and secondary liver malignancies. This review provides and overview of the currently available evidence of HAI, taking into account tumor response and long-term oncologic outcome. Summary In colorectal liver metastases (CRLM), HAI in combination with systemic therapy leads to high response rates (85-90%) and conversion to resectablity in primary unresectable disease in up to 50%. HAI in combination with systemic therapy in CRLM in the adjuvant setting shows promising long-term outcomes with up to 50% 10-year survival in a large, non-randomized single center cohort. For HCC patients, response rates as high as 20-40% have been reported for HAI and long-term outcomes compare well to other therapies. Similarly, survival for patients with unresectable intrahepatic cholangiocarcinoma 3 years after treatment with HAI is reported as high as 34%, which compares well to trials of systemic therapy where 3-year-survival is usually below 5%. However, evidence is mainly limited by highly selected, heterogenous patient groups and outdated chemotherapy regimens. The largest body of evidence stems from small, often non-randomized cohorts, predominantly from highly specialized single centers. Key Message In well selected patients with primary and secondary liver malignancies, HAI might improve response rates and, possibly, long-term survival. Results of ongoing randomized trials will show whether a wider adoption of HAI is justified, particularly to increase rates of resectability in advanced malignant diseases confined to the liver.

show abstract

Section: Indication and Contraindicationmentioning

confidence: 99%

Hepatic Artery Infusion Chemotherapy for Primary and Secondary Malignancies of the Liver: State of the Art and Current High-Level Evidence

Kuemmerli,

Hess,

Dutkowski

et al. 2024

Pharmacology

View full text Add to dashboard Cite

show abstract

“…Sixty studies assessed patients with advanced liver cancer, including 17 SRs, [27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43] 27 RCTs, 16,17, two RCT protocols 69,70 and 14 observational studies. [71][72][73][74][75][76][77][78][79][80][81][82][83][84] Table 1 provides the characteristics of the included studies.…”

Section: Liver Cancermentioning

confidence: 99%

Anticancer Drugs Compared to No Anticancer Drugs in Patients with Advanced Hepatobiliary Cancer: A Mapping Review and Evidence Gap Map

Requeijo,

Bracchiglione,

Meza

et al. 2023

CLEP

View full text Add to dashboard Cite

Despite being commonly recommended, the impact of anticancer drugs (ACDs) on patient-important outcomes beyond survival for advanced hepatobiliary cancers (HBCs) may not have been sufficiently assessed. We aim to identify and map the evidence regarding ACDs versus best supportive care (BSC) for advanced HBCs, considering patient-centered outcomes. Methods: In this mapping review, we included systematic reviews, randomized controlled trials, quasi-experimental, and observational studies comparing ACDs (chemotherapy, immunotherapy, biological/targeted therapy) versus BSC for advanced HBCs. We searched MEDLINE (PubMed), EMBASE (Ovid), Cochrane Library, Epistemonikos, PROSPERO and clinicaltrials.gov for eligible studies. Two reviewers performed the screening and data extraction processes. We developed evidence maps for each type of cancer. Results: We included 87 studies (60 for advanced liver cancer and 27 for gallbladder or bile duct cancers). Most of the evidence favored ACDs for survival outcomes, and BSC for toxicity. We identified several evidence gaps for non-survival outcomes, including quality of life or quality of end-of-life care. Discussion: Patient-important outcomes beyond survival in advanced HBCs are insufficiently assessed by the available evidence. Future studies need to address these gaps to better inform decision-making processes.

show abstract

Sorafenib

2022

Reactions Weekly

View full text Add to dashboard Cite

Hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma with portal vein thrombosis: a case–control study

Cited by 6 publications

References 25 publications

Hepatic Artery Infusion Chemotherapy for Primary and Secondary Malignancies of the Liver: State of the Art and Current High-Level Evidence

Hepatic Artery Infusion Chemotherapy for Primary and Secondary Malignancies of the Liver: State of the Art and Current High-Level Evidence

Anticancer Drugs Compared to No Anticancer Drugs in Patients with Advanced Hepatobiliary Cancer: A Mapping Review and Evidence Gap Map

Sorafenib

Contact Info

Product

Resources

About